AnaBios Closes Financing With Ampersand Capital Partners
Summary
The expected global reach and enhanced capabilities will help catalyze a larger number of successful clinical trials because more candidate molecules will be developed with the aid of our translational models. AnaBios has already strongly impacted the fields of cardiovascular disease, pain research and cardiac safety and we look forward to working with the team to accelerate the companys expansion plan. As a preclinical CRO, AnaBios has the most extensive network of hospitals and transplant centers for obtaining human tissue samples from ethically consented donors for ex vivo analysis. For more information about AnaBios, visit http://www.anabios.com.Founded in 1988, Ampersand is a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams.